Machine learning-assisted staging classification of non-small cell lung cancer using routine laboratory parameters

Background Non-small cell lung cancer (NSCLC) is one of the most prevalent malignancies worldwide. The stage at diagnosis guides treatment strategies and strongly influences clinical outcomes. This study aimed to develop a machine learning-based model using routine laboratory parameters to assist in the staging classification of NSCLC. Methods A total of 1,240 patients with pathologically confirmed NSCLC were retrospectively included. Sixty-seven laboratory parameters and three clinical variables were collected prior to treatment. Patients were randomly assigned to a training set (70%) and a validation set (30%). eXtreme Gradient Boosting (XGBoost) and logistic regression (LR) models were developed to distinguish early-stage disease (TNM stages I-II) from advanced-stage disease (TNM stages III-IV). Model performance was evaluated using receiver operating characteristic (ROC) curves, bootstrap resampling, and decision curve analysis (DCA). Interpretability was assessed using SHapley Additive exPlanations (SHAP). Subgroup analyses were conducted for patients with adenocarcinoma (ADC) and squamous cell carcinoma (SCC). Results In the validation set, the XGBoost model achieved a higher area under the curve (AUC) than the LR model (0.875 vs. 0.834, DeLong test, p = 0.0061), with higher specificity and accuracy. SHAP analysis identified carcinoembryonic antigen (CEA), sialic acid, and fibrinogen as the most influential predictors. Subgroup analysis showed strong discriminative performance of the XGBoost model in patients with ADC, whereas both models showed limited discrimination in SCC. DCA indicated that the XGBoost model provided a net benefit across a range of clinically relevant threshold probabilities. Conclusion The XGBoost model based primarily on routine laboratory parameters showed good discrimination for NSCLC staging and may serve as a noninvasive adjunct for preliminary risk stratification.

Authors

Institutions

Publication Details

Journal
Frontiers in Molecular Biosciences
Published
2026-11-16
DOI
https://doi.org/10.3389/fmolb.2026.1999345
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Machine learning-assisted staging classification of non-small cell lung cancer using routine laboratory parameters

Chenhao Zhao, Guixia Li, Yanting Zhu, Yuqian Li et al.
4 links
Frontiers in Molecular Biosciences
Lung Cancer Diagnosis and Treatment
article

Machine learning-assisted staging classification of non-small cell lung cancer using routine laboratory parameters

Chenhao Zhao, Guixia Li, Yanting Zhu, Yuqian Li, Chunxue Sun, Ke Li, Chenyang Xiao, Yeteng Mu
article en

Abstract

Background Non-small cell lung cancer (NSCLC) is one of the most prevalent malignancies worldwide. The stage at diagnosis guides treatment strategies and strongly influences clinical outcomes. This study aimed to develop a machine learning-based model using routine laboratory parameters to assist in the staging classification of NSCLC. Methods A total of 1,240 patients with pathologically confirmed NSCLC were retrospectively included. Sixty-seven laboratory parameters and three clinical variables were collected prior to treatment. Patients were randomly assigned to a training set (70%) and a validation set (30%). eXtreme Gradient Boosting (XGBoost) and logistic regression (LR) models were developed to distinguish early-stage disease (TNM stages I-II) from advanced-stage disease (TNM stages III-IV). Model performance was evaluated using receiver operating characteristic (ROC) curves, bootstrap resampling, and decision curve analysis (DCA). Interpretability was assessed using SHapley Additive exPlanations (SHAP). Subgroup analyses were conducted for patients with adenocarcinoma (ADC) and squamous cell carcinoma (SCC). Results In the validation set, the XGBoost model achieved a higher area under the curve (AUC) than the LR model (0.875 vs. 0.834, DeLong test, p = 0.0061), with higher specificity and accuracy. SHAP analysis identified carcinoembryonic antigen (CEA), sialic acid, and fibrinogen as the most influential predictors. Subgroup analysis showed strong discriminative performance of the XGBoost model in patients with ADC, whereas both models showed limited discrimination in SCC. DCA indicated that the XGBoost model provided a net benefit across a range of clinically relevant threshold probabilities. Conclusion The XGBoost model based primarily on routine laboratory parameters showed good discrimination for NSCLC staging and may serve as a noninvasive adjunct for preliminary risk stratification.

Frontiers in Molecular BiosciencesVol. 13
Heze Municipal Hospital (CN), Shandong First Medical University (CN)
Good health and well-being
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon